Oxford, UK, 16 July 2024 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today that it has appointed Dr. Mark Bodmer as Chief Executive Officer with effect from 24 July.

Mark’s appointment follows the stepping down of Dr Danuta Jeziorska, Nucleome’s Founding CEO and Scientific Co-Founder. Dr Jeziorska led the spin-out of Nucleome as the first female scientific founder from the Weatherall Institute of Molecular Medicine at Oxford University in 2019, bringing $55m and a top-tier investment syndicate into the business. Since then, she has led the Company in developing a highly productive innovative platform that has enabled the discovery of a portfolio of first-in-class targets through dark genome’s genetics with the most advanced candidate now in drug discovery.

Dr Jeziorska said: “It has been a privilege to lead and work with such an incredible team at Nucleome. We have achieved so much together, and I could not be more proud. I founded Nucleome through passion and ambition to bring curative treatments to patients. I am incredibly proud that we have now discovered a portfolio of targets and have entered drug discovery to fulfil this vision. The business is in a very strong position and set for future success. I am grateful for the support of the investors and the team.”

Dr Russell Greig, Chair of the Board, added: “Danuta’s vision, combined with strong ambition, strategic foresight and steadfast guidance have led the company to the strong position it enjoys today. On behalf of the Board and the Executive team, I want to thank Danuta for her unwavering dedication and leadership in building Nucleome.”

– Ends –